Details of the Drug Pharmacogenomic Perturbation Atlas

Mepyramine Drug Info

Anhistabs; Anhistol; Antalergan; Antallergan; Antamine; Anthisan; Copsamine; Coradon; Dipane; Dorantamin; Harvamine; Histacap; Histalon; Histapyran; Histasan; Isamin; Kriptin; Maranhist; Mepiramina; Mepiramine; Mepyramin; Mepyraminum; Mepyren; Neoantergan; Neobridal; Nyscaps; PYRA; Paraminyl; Parmal; Pyramal; Pyranisamine; Pyrilamide; Pyrilamine; Stamine; Stangen; Statomin; Thylogen; Mepyramin [German]; Pyrilamine salt with fine resin; RP 2786; [3H]mepyramine; [3H]pyrilamine; Afko-Hist; Mepiramina [INN-Spanish]; Mepyramine (INN); Mepyramine [INN:BAN]; Mepyraminum [INN-Latin]; Neo-Bridal; Wait's green mountain antihistamine; R.d. 2786; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin; P-Methoxybenzyl-alpha-pyridyl-dimethyl-aethylendiamin [German]; P-Methoxy-benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyridin-2-amine; N-p-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-para-Methoxybenzyl-N',N'-dimethyl-N-alpha-pyridylethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N-(para-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridylethylenediamine; N',N'-Dimethyl-N-(p-methoxybenzyl)-N-(2-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Dimethylamino-aethyl-N-p-methoxy-benzyl-.alpha.-amino-pyridin-maleat; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-(alpha.-pyridyl)ethylenediamine; N-(p-Methoxybenzyl)-N',N'-dimethyl-N-2-pyridyl-1,2-ethanediamine; N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-((4-Methoxyphenyl)methyl)-N',N'-dimethyl-N-2-pyridinyl-1,2-ethanediamine; N-(4-methoxybenzyl)-N',N'-dimethyl-N-pyridin-2-ylethane-1,2-diamine; N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine; 2-((2-(Dimethylamino)ethyl)-(p-methoxybenzyl)amino)pyridine; 2-((p-Methoxybenzyl)(2-(dimethylamino)ethyl)amino)pyridine; 2-[(p-Methoxybenzyl)[2-(dimethylamino)ethyl]amino]pyridine; 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine; 2-[[2-(Dimethylamino)ethyl]-(p-methoxybenzyl)amino]pyridine; 2-dimethylaminoethyl-p-anisyl-(2-pyridyl)amine

Therapeutic Class

Antiasthmatic Agents

Cross-matching ID

PubChem CID

4992

ChEBI ID

CHEMBL6762

CAS Number

CAS 91-84-9

TTD Drug ID

D08JZS

VARIDT Drug ID

DR00564

General Information of Drug (ID: DMB4SFH)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Legionellosis	1.75	2.30e-1	51/57 (89.47%)	HSPA8;CXCL8;CXCL1;...
Antigen processing and presentation	1.50	4.74e-1	60/78 (76.92%)	HSPA8;HSPA2;TAPBP;...
Base excision repair	1.49	4.49e-1	29/33 (87.88%)	PCNA;PARP2;POLE2;...
Progesterone-mediated oocyte maturation	1.48	4.31e-1	75/100 (75%)	PRKACB;IGF1R;CCNA2;...
African trypanosomiasis	1.47	4.02e-1	32/37 (86.49%)	HBB;PLCB1;GNAQ;...
Arginine and proline metabolism	1.46	3.84e-1	39/50 (78%)	AOC1;P4HA1;SAT1;...
Nucleotide excision repair	1.46	3.65e-1	40/47 (85.11%)	RAD23B;RFC2;RFC5;...
Measles	1.44	3.86e-1	133/139 (95.68%)	HSPA8;HSPA2;TLR4;...
GnRH secretion	1.44	3.58e-1	60/64 (93.75%)	SPP1;PLCB1;ARRB2;...
Cortisol synthesis and secretion	1.44	3.45e-1	58/65 (89.23%)	PLCB1;PBX1;AGTR1;...
Spliceosome	1.43	3.48e-1	101/150 (67.33%)	HSPA8;HSPA2;SNRPB;...
Rheumatoid arthritis	1.42	3.58e-1	78/93 (83.87%)	CXCL8;CXCL1;CXCL3;...
Apelin signaling pathway	1.40	3.77e-1	117/137 (85.4%)	SPP1;PLCB1;PLAT;...
Cell cycle	1.40	3.59e-1	110/124 (88.71%)	RBL2;GADD45G;CCNA2;...
Phosphonate and phosphinate metabolism	1.39	3.82e-1	5/6 (83.33%)	CEPT1;CHPT1
Malaria	1.37	4.00e-1	44/50 (88%)	HBB;CXCL8;COMP;...
T cell receptor signaling pathway	1.36	4.29e-1	93/104 (89.42%)	ITK;CD4;PRKCQ;...
NOD-like receptor signaling pathway	1.35	4.28e-1	145/181 (80.11%)	CXCL8;CXCL1;NAMPT;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	1.35	4.11e-1	79/89 (88.76%)	BATF3;TLR4;CSNK2A2;...
RNA transport	1.35	4.06e-1	128/186 (68.82%)	EIF1AY;RPP40;EIF4A1;...
Amoebiasis	1.34	4.05e-1	99/102 (97.06%)	CXCL8;CXCL1;PLCB1;...
beta-Alanine metabolism	1.34	3.93e-1	25/30 (83.33%)	ALDH3A1;ALDH6A1;GAD1;...
Vascular smooth muscle contraction	1.32	4.34e-1	113/133 (84.96%)	PLA2G2A;RAMP1;PLCB1;...
Endocytosis	1.26	4.67e-1	198/252 (78.57%)	HSPA8;HSPA2;DNAJC6;...
Primary bile acid biosynthesis	1.26	4.69e-1	15/17 (88.24%)	AMACR;CYP39A1;SLC27A5;...
IL-17 signaling pathway	1.26	4.60e-1	84/94 (89.36%)	CXCL8;CXCL1;LCN2;...
Sphingolipid signaling pathway	1.25	4.55e-1	106/119 (89.08%)	PLCB1;CERS6;FCER1A;...
Th1 and Th2 cell differentiation	1.25	4.47e-1	80/92 (86.96%)	JAG1;HLA-DRA;CD4;...
Phagosome	1.25	4.50e-1	118/152 (77.63%)	C1R;COMP;COLEC12;...
Spinocerebellar ataxia	1.24	4.62e-1	128/143 (89.51%)	RORA;PLCB1;PSMB3;...
Relaxin signaling pathway	-1.26	5.58e-1	114/129 (88.37%)	MAPK1;COL1A2;MAP2K7;...
Glutathione metabolism	-1.27	5.51e-1	43/57 (75.44%)	GSR;LAP3;IDH1;...
Ras signaling pathway	-1.28	5.51e-1	201/232 (86.64%)	GRIN2A;RIN1;RASGRF1;...
Linoleic acid metabolism	-1.28	5.52e-1	21/29 (72.41%)	CYP3A4;PLAAT3;CYP2C8;...
PI3K-Akt signaling pathway	-1.28	5.67e-1	317/354 (89.55%)	THBS3;ITGB7;IL7R;...
Small cell lung cancer	-1.31	4.78e-1	90/92 (97.83%)	TRAF3;LAMA4;CASP9;...
Adipocytokine signaling pathway	-1.32	4.91e-1	64/69 (92.75%)	RXRG;ADIPOR2;ACACB;...
Arginine biosynthesis	-1.32	5.09e-1	17/22 (77.27%)	GLS2;GLUD1;GLS;...
Arrhythmogenic right ventricular cardiomyopathy	-1.32	5.31e-1	70/77 (90.91%)	CACNG3;ITGB7;ITGA10;...
Hypertrophic cardiomyopathy	-1.33	5.09e-1	81/90 (90%)	ITGA2;TTN;ITGA5;...
Bacterial invasion of epithelial cells	-1.35	4.79e-1	59/77 (76.62%)	ITGA5;CAV1;PIK3CA;...
Asthma	-1.35	4.91e-1	25/31 (80.65%)	EPX;HLA-DOB;PRG2;...
Bile secretion	-1.36	4.86e-1	68/90 (75.56%)	NR0B2;SLC4A2;ATP1A3;...
Central carbon metabolism in cancer	-1.37	4.76e-1	67/70 (95.71%)	GLS2;HIF1A;MTOR;...
Aminoacyl-tRNA biosynthesis	-1.38	4.82e-1	15/66 (22.73%)	TARS2;GATB;CARS2;...
Galactose metabolism	-1.39	4.76e-1	26/31 (83.87%)	GALE;HK2;G6PC2;...
Lysosome	-1.43	3.56e-1	115/128 (89.84%)	SGSH;TCIRG1;GGA2;...
Maturity onset diabetes of the young	-1.45	3.28e-1	21/26 (80.77%)	IAPP;NEUROD1;INS;...
Proteoglycans in cancer	-1.47	3.20e-1	172/205 (83.9%)	CTTN;MTOR;SLC9A1;...
Protein digestion and absorption	-1.49	2.84e-1	78/103 (75.73%)	CTRL;COL11A2;SLC7A9;...
ABC transporters	-1.50	2.96e-1	37/45 (82.22%)	ABCA6;ABCA1;ABCA7;...
Focal adhesion	-1.50	3.29e-1	180/201 (89.55%)	TLN1;PTEN;TLN2;...
Renin-angiotensin system	-1.51	3.36e-1	20/23 (86.96%)	ENPEP;MME;CTSA;...
Steroid hormone biosynthesis	-1.56	2.65e-1	43/61 (70.49%)	UGT2B4;HSD11B1;STS;...
Proximal tubule bicarbonate reclamation	-1.58	2.54e-1	21/23 (91.3%)	ATP1B1;GLUD2;CA4;...
ECM-receptor interaction	-1.61	2.19e-1	80/88 (90.91%)	THBS3;ITGB7;LAMA4;...
Mineral absorption	-1.65	1.98e-1	48/60 (80%)	ATP1A3;ATP7A;SLC34A2;...
Sulfur metabolism	-1.75	9.53e-2	9/10 (90%)	PAPSS1;MPST;SUOX;...
Nitrogen metabolism	-1.78	8.10e-2	16/17 (94.12%)	CPS1;GLUD2;CA4;...
Primary immunodeficiency	-1.82	9.53e-2	33/38 (86.84%)	CD8A;JAK3;RFX5;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	1.25uM - 40uM	3H, 6H, 24H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	12uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H